Crossmark

The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study

Crossref DOI link: https://doi.org/10.1186/s13098-024-01526-2

Published Online: 2024-12-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gameil, Mohammed Ali https://orcid.org/0000-0002-9342-6451
Yousef, Elshahat Ali Ahmed Mohamed https://orcid.org/0000-0001-8823-4837
Marzouk, Rehab Elsayed https://orcid.org/0000-0002-5551-1540
Emara, Mohamed H. https://orcid.org/0000-0002-1504-7851
Abdelkader, Abeer H. https://orcid.org/0000-0003-3588-0389
Salama, Rasha Ibrahim https://orcid.org/0000-0001-6285-8465
Funding

Funding for this research was provided by:

Mansoura University
License Information

Text and Data Mining valid from 2024-12-04

Version of Record valid from 2024-12-04
More Information

Article History

Received: 23 August 2024

Accepted: 13 November 2024

First Online: 4 December 2024

Declarations

:

: This study was approved by the Institutional Review Board for Clinical Research committee of Mansoura University with approval code (No. R.22.10. 1897.R1) and with the IRB committee, Al Yousif Hospital, Alkhobar, Saudi Arabia, (AYH IRB: 02/03/2023). All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and later versions.Written informed consent was approved by the IRB and signed by all participants before enrolment.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below